CN116940350A - 预防、治疗或改善溃疡性结肠炎的阿米莫德 - Google Patents

预防、治疗或改善溃疡性结肠炎的阿米莫德 Download PDF

Info

Publication number
CN116940350A
CN116940350A CN202280013674.8A CN202280013674A CN116940350A CN 116940350 A CN116940350 A CN 116940350A CN 202280013674 A CN202280013674 A CN 202280013674A CN 116940350 A CN116940350 A CN 116940350A
Authority
CN
China
Prior art keywords
dose
subject
mode
administration period
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280013674.8A
Other languages
English (en)
Chinese (zh)
Inventor
J•李
N•斯拉特金
E•R•罗威
Z•海曼森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch Health Ireland Ltd
Original Assignee
Bausch Health Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch Health Ireland Ltd filed Critical Bausch Health Ireland Ltd
Publication of CN116940350A publication Critical patent/CN116940350A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Luminescent Compositions (AREA)
  • Cereal-Derived Products (AREA)
CN202280013674.8A 2021-02-08 2022-02-08 预防、治疗或改善溃疡性结肠炎的阿米莫德 Pending CN116940350A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147060P 2021-02-08 2021-02-08
US63/147,060 2021-02-08
PCT/EP2022/053030 WO2022167690A1 (en) 2021-02-08 2022-02-08 Amiselimod for preventing, treating, or ameliorating ulcerative colitis

Publications (1)

Publication Number Publication Date
CN116940350A true CN116940350A (zh) 2023-10-24

Family

ID=80447376

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280013674.8A Pending CN116940350A (zh) 2021-02-08 2022-02-08 预防、治疗或改善溃疡性结肠炎的阿米莫德

Country Status (9)

Country Link
US (1) US20240299318A1 (https=)
EP (1) EP4288041A1 (https=)
JP (1) JP2024506041A (https=)
CN (1) CN116940350A (https=)
AU (1) AU2022217475A1 (https=)
CA (1) CA3207440A1 (https=)
MX (1) MX2023009249A (https=)
TW (1) TW202245742A (https=)
WO (1) WO2022167690A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025134072A1 (en) * 2023-12-21 2025-06-26 Bausch Health Ireland Limited Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
BRPI0619894B8 (pt) 2005-12-15 2021-05-25 Mitsubishi Tanabe Pharma Corp composto de amina e composição farmacêutica
JP5657565B2 (ja) 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
MA40774A (fr) * 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
PL3242666T3 (pl) * 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
JP2018527406A (ja) * 2015-08-11 2018-09-20 アカール ファーマ ピーティーワイ リミテッドＡｋａａｌ Ｐｈａｒｍａ Ｐｔｙ Ｌｔｄ Ｓ１ｐ受容体モジュレーターを含む組成物
WO2020051568A1 (en) * 2018-09-08 2020-03-12 Wen Tan NEW USE OF R-ENANTIOMER OF ADRENERGIC β2 RECEPTOR AGONISTS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND ITS EXTRA INTESTINAL MANIFESTATIONS

Also Published As

Publication number Publication date
EP4288041A1 (en) 2023-12-13
CA3207440A1 (en) 2022-08-11
TW202245742A (zh) 2022-12-01
JP2024506041A (ja) 2024-02-08
WO2022167690A1 (en) 2022-08-11
AU2022217475A1 (en) 2023-08-24
MX2023009249A (es) 2023-10-23
US20240299318A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
Tapson et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial
JP6244497B1 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
KR101633720B1 (ko) 지방이상증의 치료
US9737540B2 (en) Combination treatment of cancer
ES3001196T3 (es) Nuevo uso de una combinación de un bloqueador del receptor de la angiotensina (ARB) con un inhibidor de la endopeptidasa neutra (NEPI)
EP3294283B1 (en) Sacubitril-valsartan dosage regimen for treating heart failure
CZ292002B6 (cs) Léčivo pro snížení úmrtnosti způsobené městnavým selháním srdce u savců
EA034864B1 (ru) Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой
CN117677395A (zh) 长效glp1/胰高血糖素受体激动剂的剂量方案
CN105517631A (zh) 左西替利嗪和孟鲁司特在治疗创伤性损伤中的用途
CN105324112A (zh) 用于治疗腹泻的产品和方法
JP2024535095A (ja) タウロデオキシコリン酸またはその薬学的に許容可能な塩および抗ウイルス剤を有効成分として含有するコロナウイルス感染症－１９（ｃｏｖｉｄ－１９）治療用組成物
JP2025156353A (ja) 免疫調節を使用したがんの治療のための新規アプローチ
JP2024519835A (ja) タウロデオキシコール酸またはその薬学的に許容される塩を有効成分として含む新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の治療用組成物
CN116940350A (zh) 预防、治疗或改善溃疡性结肠炎的阿米莫德
EP3972599B1 (en) Combination for lowering serum phosphate in a patient
TW202535416A (zh) ９－胺基甲基美諾四環素化合物及其於治療社區肺炎（ｃａｂｐ）之用途
US20230151093A1 (en) Methods of treating immune mediated pulmonary injury
WO2025134072A1 (en) Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod
HK40094222A (zh) 预防、治疗或改善溃疡性结肠炎的阿米莫德
EA051860B1 (ru) Способ профилактики, лечения или облегчения язвенного колита
JP7657734B2 (ja) ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法
EP3638250A1 (en) Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
KR20220074913A (ko) S1p1 수용체와 관련된 상태를 치료하는 방법
US20250339442A1 (en) Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40094222

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination